美股异动｜吉利德科学跌超3% CVS暂缓将其艾滋病预防新药纳入医保名单

Core Viewpoint - Gilead Sciences (GILD.US) shares fell over 3% to $115.16 following CVS Health's decision not to include Gilead's new HIV prevention drug Yeztugo in its commercial plans due to clinical, financial, and regulatory reasons [1] Group 1: Company Developments - CVS Health's decision is based on clinical, financial, and regulatory factors [1] - Gilead is still in negotiations with CVS regarding Yeztugo [1] Group 2: Product Pricing and Market Goals - The annual list price for Yeztugo in the U.S. exceeds $28,000 [1] - Gilead aims to achieve 75% coverage by U.S. insurers by the end of the year and 90% coverage by June 2026 [1]